Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common ADHD drug ease chronic fatigue brain fog?

NCT ID NCT01071044

Symptom relief Sponsor: Rochester Center for Behavioral Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether lisdexamfetamine dimesylate (Vyvanse), a drug used for ADHD, can help with cognitive impairment and fatigue in adults with chronic fatigue syndrome. Twenty-six participants were randomly assigned to receive either Vyvanse or a placebo for six weeks. The researchers measured changes in executive function and fatigue levels to see if the drug offered any benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lisdexamfetamine dimesylate (Vyvanse)
What this could lead to
If it works, this could point toward a treatment for the cognitive problems and fatigue that often come with chronic fatigue syndrome.
What could go wrong
This is a small, early-phase study with only 26 participants, so results may not apply to everyone. Stimulants like Vyvanse can cause side effects such as increased heart rate, anxiety, or insomnia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

26 people

The number who actually took part.

Start date

Nov 2009

Finished

Mar 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BRIEF-A Global Executive Composite score (GEC) ≥ 65, or Behavioral Regulation Index score (BRI) ≥ 65, or Metacognition Index score (MI) ≥ 65. * Subjects must meet consensus criteria for chronic fatigue syndrome. * Provide written informed consent for participation in the trial before completing any study-related procedures. * 18-60 years at time of consent * Male or non-pregnant females who are not breastfeeding. * Females of reproductive potential must agree to use a medically accepted means of contraception when engaging in sexual intercourse at any time during the study. * Are able to swallow study medication. Exclusion Criteria: * CFS and executive functioning impairment are not present or not diagnosable * Serious comorbid psychiatric condition * Subjects who were pregnant, nursing, or intended to become pregnant * Subjects who had been on a psychostimulant regimen in the last six months * Subjects who had a medical condition that would have been affected by psychostimulant medication * Subjects who were of low intelligence, or who were unable to communicate effectively with the study team

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic fatigue syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic fatigue syndrome Cognitive impairments

Contacts and locations

Locations

  • Rochester Center for Behavioral Medicine

    Rochester Hills, Michigan, 48307, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.